With a ros­ter of gene ther­a­py vets, For­bion makes a bet on 'rel­a­tive­ly emp­ty space' of vec­tor­ized an­ti­bod­ies

The fu­ture waves of gene ther­a­py could look quite dif­fer­ent from the gene re­place­ment of­fer­ings cur­rent­ly on the mar­ket, For­bion reck­ons.

It’s the key idea be­hind Vec­to­rY, a start­up seed­ed by the Eu­ro­pean VC firm that’s out to de­vel­op vec­tor­ized an­ti­bod­ies for mus­cu­lar and neu­rode­gen­er­a­tive dis­or­ders.

Voy­ager Ther­a­peu­tics, which briefly pushed the tech­nol­o­gy to the lime­light with its short-lived Ab­b­Vie col­lab­o­ra­tion, is among the “sev­er­al oth­er com­pa­nies work­ing on it too, but def­i­nite­ly it’s a pret­ty rel­a­tive­ly emp­ty space,” said Mar­co Boors­ma — a gen­er­al part­ner at For­bion who’s step­ping in as in­ter­im CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER